Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07675603

Low-carbohydrate Diet and Low-Density Lipoprotein – Cholesterol (LDL-c) Interindividual Variability

Low-carbohydrate Diet and Low-Density Lipoprotein – Cholesterol (LDL-c) Interindividual Variability — Recruiting • Non-phase study • Oncology • NCT07675603.

📅 30 Jun 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07675603
Sponsor
University of Bath
Start
2026-02-05
ClinicaliQ Trial Snapshot
  • Low-carbohydrate Diet and Low-Density Lipoprotein – Cholesterol (LDL-c) Interindividual Variability — Recruiting • Non-phase study • Oncology • NCT07675603.
  • What is being tested: The trial investigates how individual patients respond differently to low-carbohydrate (ketogenic) diets in terms of LDL-cholesterol changes, recognising that the same dietary intervention produces variable lipid outcomes between individuals.
  • Patient eligibility overview: The study enrolls adults without drug-resistant epilepsy who are suitable for ketogenic diet intervention, examining the metabolic and genetic factors that explain why some individuals experience beneficial versus unfavourable LDL-cholesterol responses.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Ketogenic diets are very low-carbohydrate diets that increase hepatic production of ketone bodies, which have several effects as substrates and signals. Ketogenic diets are used to manage some conditions (e.g., drug-resistant epilepsy), and their potential for managing many other conditions (e.g., cancer) is being actively explored. Indeed, the British Dietetic Association acknowledge the potential for ketogenic diets to improve glycaemic control to a greater extent than some other diets in people with type 2 diabetes. A lower fasting glucose is also relevant to future mortality in people without diabetes. Ketogenic…

Eligibility Snapshot
  • : * Age: >18 years * Body mass index: 18.5-35 kg·m-2 * Low-Density Lipoprotein-cholesterol 5.4 mmol/L) * dietary intolerances or allergies or to other study procedures * diagnosis of gastrointestinal disorders * any other condition/medication that could introduce bias to the study * already following a ketogenic diet * not willing to follow a ketogenic diet * unable to understand English language

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer
Oncology · 24 Jun 2026
Mirvetuximab soravtansine is recommended for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients with folate receptor-alpha (FRα) positivity—confirm FRα…
View guideline →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Guideline
Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia
Oncology · 19 Aug 2026
Use acalabrutinib with venetoclax ± obinutuzumab as first-line treatment for untreated CLL – this combination is recommended by NICE and offers improved…
View guideline →
Clinical Brief
Very hot drinks may damage the food pipe and increase cancer risk
Oncology · BBC Health · 09 Sep 2026
The International Agency for Research on Cancer (IARC) has classified drinking "very hot" beverages (>65°C) as a probable carcinogen (Group 2A), associated…
View brief →
Guideline
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma
Oncology · 19 Aug 2026
First-line treatment option: Acalabrutinib combined with bendamustine and rituximab is recommended as a first-line treatment for untreated mantle cell lymphoma, offering an…
View guideline →
Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →